Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone.

Furthermore, lungs of animals that were treated with the SAM and anti-PD-1 combination showed the smallest total metastatic lesion area compared to all groups, though the difference did not reach statistical significance compared to either monotherapy ( Figure 4 A,B).

also in 111,027 other papers

The combination treatment also had the maximum percentage of tumor growth inhibition (TGI) at 82% compared to the control (0%), SAM (58%), and anti-PD-1 antibody (66%), although the TGI difference between the combination treatment and anti-PD-1 antibody alone was barely significant ( Figure 3 B).

also in 875 other papers